FrancophonIA/ELRC3.0 huggingface dataset:
English: When prescribing Prevenar 13, consideration should be given to the risk of invasive disease and pneumonia in the different age groups, other diseases the vaccinees may have and the type of bacteria in the different geographical areas.
Estonian: Prevenar 13 määramisel tuleb arvestada invasiivse haiguse ja kopsupõletiku tekkeriski eri vanuserühmades, vaktsineeritute võimalikke kaasuvaid haigusi ja eri geograafiliste piirkondade erinevaid bakteritüüpe.
English: Where the response to Prevenar 13 was lower than the comparator, the differences were considered to be small.
Estonian: Juhtudel, kus vastus vaktsiinile Prevenar 13 oli väiksem kui võrdlusravimil, oli erinevus väike.
English: Invasive disease occurs when the bacterium spreads through the body causing serious infections such as septicaemia (blood infection) and meningitis (infection of the membranes around the brain and spine).
Estonian: Invasiivne haigus tekib, kui bakter levib kogu organismis, põhjustades raskeid nakkusi, näiteks sepsist (nakkusveresust) ja meningiiti (ajukelmepõletikku).
English: For the prevention of pneumonia, although the use of Prevenar 13 was only investigated in adults over 65 years of age, the CHMP considered that the results could also be applied to younger adults as studies have shown that their immune response is similar or higher than that among adults older than 65.
Estonian: Kuigi vaktsiini Prevenar 13 kasutamist kopsupõletiku ennetamiseks uuriti ainult üle 65-aastastel täiskasvanutel, järeldas inimravimite komitee, et tulemused kehtivad ka nooremate täiskasvanute korra, sest uuringud on näidanud, et nende immuunvastus on sarnane või parem kui üle 65-aastaste täiskasvanute oma.
English: This is a summary of the European public assessment report (EPAR) for Prevenar 13.
Estonian: See on vaktsiini Prevenar 13 Euroopa avaliku hindamisaruande kokkuvõte.
English: In adults, Prevenar 13 was investigated in four main studies.
Estonian: Täiskasvanutel uuriti vaktsiini Prevenar 13 neljas põhiuuringus.
English: It is also used to protect adults and the elderly against invasive disease and pneumonia caused by S. pneumoniae.
Estonian: Seda kasutatakse ka täiskasvanud ja eakate patsientide kaitsmiseks bakteri S. pneumoniae põhjustatud invasiivse haiguse ja kopsupõletiku eest.
English: These polysaccharides have been purified, then ‘conjugated' (attached) to a carrier to help them to be recognised by the immune system.
Estonian: Polüsahhariidid on puhastatud ja seejärel konjugeeritud (kinnitatud) kandeainele, et immuunsüsteem need paremini ära tunneks.
English: The vaccine is also ‘adsorbed' (fixed) onto an aluminium compound to enhance the immune response.
Estonian: Vaktsiin on adsorbeeritud (fikseeritud) parema ravivastuse stimuleerimiseks ka alumiiniumiühendile.
English: The CHMP decided that Prevenar 13's benefits are greater than its risks and recommended that it be granted marketing authorisation.
Estonian: Inimravimite komitee otsustas, et vaktsiini Prevenar 13 kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda vaktsiini müügiloa.
English: The first three doses are given with an interval of one month between each dose.
Estonian: Esimese kolme annuse korral jäetakse iga annuse vahele üks kuu.
English: In children, the ability of Prevenar 13 to trigger the production of antibodies (immunogenicity) was assessed in two main studies involving 1,266 healthy children who were vaccinated between the ages of two and 15 months and in a third study involving 598 children aged between five and 17 years old who had previously been vaccinated with Prevenar or who had never been vaccinated for invasive pneumococcal disease.
Estonian: Lastel hinnati vaktsiini Prevenar 13 omadust tekitada antikehi (immunogeensust) kahes põhiuuringus, kus osales 1266 tervet last, keda vaktsineeriti 2-15-kuuselt, ja kolmandas uuringus, kus osales 598 last vanuses 5-17 aastat, keda oli varem vaktsineeritud Prevenariga või keda ei olnud varem vaktsineeritud invasiivse pneumokokkhaiguse vastu.
English: This was true for five of the six additional polysaccharides in the second study.
Estonian: Teises uuringus toimus see 5 täiendava polüsahhariidi korral 6st.
English: For more information about treatment with Prevenar 13, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate vaktsiiniga Prevenar 13 toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: Why has Prevenar 13 been approved?
Estonian: Miks Prevenar 13 heaks kiideti?
English: Other information about Prevenar 13
Estonian: Muu teave vaktsiini Prevenar 13 kohta
English: In adults and the elderly, the Committee noted that community-acquired pneumonia and invasive pneumococcal disease may be an important health problem and that the benefit in terms of protection outweighed the risk of adverse reactions.
Estonian: Komitee märkis, et täiskasvanud ja eakatel patsientidel võib keskkonnatekkene kopsupõletik ja invasiivne pneumokokkhaigus põhjustada raskeid terviseprobleeme ja kaitse kasulikkus on suurem kui kõrvalnähtude risk.
English: The main measure of effectiveness was based on the number of subjects who developed a first episode of pneumonia caused by a type of S. pneumoniae covered by Prevenar 13.
Estonian: Efektiivsuse põhinäitaja oli nedne osalejate arv, kellel tekkis kopsupõletiku esimene episood, mille põhjustas bakteri S. pneumoniae tüüp, mida sisaldab Prevenar 13.
English: The Committee also noted that Prevenar 13 contains additional polysaccharides from the types of S. pneumoniae that are responsible for causing disease in children in Europe.
Estonian: Komitee märkis ka, et Prevenar 13 sisaldab bakteri S. pneumoniae selliste tüüpide täiendavaid polüsahhariide, mis põhjustavad laste haigestumist Euroopas.
English: Prevenar 13 was compared with Prevenar.
Estonian: Vaktsiini Prevenar 13 võrreldi Prevenariga.
English: Alternatively, when Prevenar 13 is given as part of a routine immunisation programme, two doses can be given at the ages of two and four months, followed by a booster at 11 to 15 months of age;
Estonian: Teise võimalusena, kui vaktsiini Prevenar 13 manustatakse imikute korralise immuniseerimisprogrammi raames, antakse kaks annust, esimene 2 kuu ja teine 4 kuu vanuses, ning seejärel antakse tugevdav annus 11-15 kuu vanuses.
English: • children between 12 and 23 months of age should receive two doses with an interval of at least two months;
Estonian: • 12-23-kuused lapsed peavad saama kaks annust vaheajaga vähemalt kaks kuud.
English: The CHMP noted that in children the immune system's response to Prevenar 13 was comparable to that of Prevenar, which is already authorised for the protection of children against S. pneumoniae in the EU.
Estonian: Inimravimite komitee märkis, et laste immuunsüsteemi vastus vaktsiinile Prevenar 13 oli võrreldav Prevenari vastusega, millel juba on Euroopa Liidus müügiluba laste kaitsmiseks bakteri S. pneumoniae vastu.
English: A fourth study involved approximately 85,000 adults over 65 year of age who had not previously been vaccinated with the 23-valent polysaccharide vaccine, and compared Prevenar 13 with placebo (a dummy treatment).
Estonian: Neljandas uuringus osales ligikaudu 85 000 üle 65-aastast täiskasvanut, keda ei olnud varem vaktsineeritud 23-valentse polüsahhariidvaktsiiniga, ning võrreldi vaktsiini Prevenar 13 platseeboga (näiv ravim).
English: • children between two and 17 years of age should receive a single dose.
Estonian: • 2-17-aastased lapsed peavad saama ühe ühekordse annuse.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Prevenar 13.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas vaktsiini ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas vaktsiini kasutada.
English: In the first two studies they were compared directly, and in the third study the results for Prevenar 13 were compared to those obtained for Prevenar in a previous study.
Estonian: Esimeses kahes uuringus võrreldi vaktsiine vahetult, kolmandas võrreldi vaktsiini Prevenar 13 tulemusi Prevenari varasema uuringu tulemustega.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Prevenar 13, including the appropriate precautions to be followed by healthcare professionals and patients.
Estonian: Selle alusel lisati vaktsiini Prevenar 13 omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
English: In adults and the elderly, the most common side effects (seen in more than 1 patient in 10) are decreased appetite, headaches, diarrhoea, fever (only very common in adults aged 18 to 29 years), vomiting (only very common in adults aged 18 to 49 years), rash, reactions at the site of injection, limitation of arm movement, arthralgia and myalgia (joint and muscle pain), chills and fatigue.
Estonian: Kõige sagedamad kõrvalnähud (esinenud enam kui 1 patsiendil 10st) täiskasvanud ja eakatel patsientidel on isutus, peavalu, kõhulahtisus, palavik (sage üksnes 18-29-aastastel täiskasvanutel), oksendamine (sage üksnes 18-49-aastastel täiskasvanutel), lööve, süstekoha reaktsioonid, käsivarre piiratud liigutamisvõime, liigesevalu, lihasevalu, külmavärinad ja väsimus.
English: Prevenar 13 can be used in children who have started vaccination with Prevenar (another vaccine authorised in the European Union for S. pneumoniae, which contains parts of seven of the 13 types of S. pneumoniae included in Prevenar 13).
Estonian: Vaktsiini Prevenar 13 tohib kasutada lastel, keda on juba hakatud vaktsineerima Prevenariga (vaktsiin, millel juba on Euroopa Liidus müügiluba bakteri S. pneumoniae raviks ja mis sisaldab vaktsiinis Prevenar 13 sisalduvast bakteri S. pneumoniae 13 tüübist 7 tüüpi).
English: It is available as a suspension for injection that contains parts from 13 different types of the bacterium Streptococcus pneumoniae (S. pneumoniae).
Estonian: Seda turustatakse süstesuspensioonina, mis sisaldab bakteri Streptococcus pneumoniae (S. pneumoniae) 13 eri tüübi osi.
English: The additional studies showed that Prevenar 13 led to an increase in antibody production following booster vaccinations and supported a switch to Prevenar 13 in children who had started vaccination with Prevenar.
Estonian: Täiendavad uuringud näitasid, et Prevenar 13 suurendas antikehade teket pärast revaktsineerimist, ja toetasid Prevenari saanud laste üleviimist vaktsiinile Prevenar 13.
English: The second study involved 938 adults aged 70 years or older who had already been vaccinated against invasive disease caused by S. pneumoniae at least five years earlier.
Estonian: Teises uuringus osales 938 vähemalt 70-aastast täiskasvanut, keda oli vähemalt 5 aastat varem vaktsineeritud bakteri S. pneumoniae põhjustatud invasiivse haiguse vastu.
English: Prevenar 13 was not shown to affect the immunogenicity of other vaccines routinely given to children.
Estonian: Ei tõendatud, et Prevenar 13 oleks mõjutanud laste muude korraliste vaktsiinide immunogeensust.
English: Further information on the use of Prevenar 13 in people at increased risk of pneumococcal infections (such as patients with HIV or people who have received a haematopoietic stem cell transplant) and on how to switch from Prevenar to Prevenar 13 can be found in the summary of product characteristics (also part of the EPAR).
Estonian: Lisateave vaktsiini Prevenar 13 manustamise kohta pneumokokkinfektsioonide suurenenud riskiga patsientidele (nt HIV-iga patsiendid või siiratud hemopoeetiliste tüvirakkudega patsiendid) või ülemineku kohta Prevenarilt vaktsiinile Prevenar 13 on ravimi omaduste kokkuvõttes (mis on samuti Euroopa avaliku hindamisaruande osa).
English: The first study involved 835 adults aged 50 to 64 years who had not previously been vaccinated against invasive disease caused by S. pneumoniae.
Estonian: Esimeses osales 835 täiskasvanut vanuses 50-64 aastat, keda ei olnud varem vaktsineeritud bakteri S. pneumoniae põhjustatud invasiivse haiguse vastu.
English: In both studies, Prevenar 13 was compared with a similar vaccine containing the polysaccharides from 23 different types of S. pneumoniae (23-valent polysaccharide vaccine).
Estonian: Mõlemas uuringus võrreldi vaktsiini Prevenar 13 ja sarnast vaktsiini, mis sisaldab bakteri S. pneumoniae 23 tüübi polüsahhariide (23-valentne polüsahhariidvaktsiin).
English: Prevenar 13 is a vaccine.
Estonian: Prevenar 13 on vaktsiin.
English: The most common side effects with Prevenar 13 (seen in more than 1 patient in 10) in children are decreased appetite, fever (only very common in children aged 6 weeks to 5 years), irritability, reactions at the site of injection (reddening or hardening of the skin, swelling, pain or tenderness), somnolence (sleepiness) and poor quality sleep.
Estonian: Vaktsiini Prevenar 13 kõige sagedamad kõrvalnähud lastel (esinenud enam kui 1 patsiendil 10st) on isutus, palavik (sage üksnes 6 nädala kuni 5 aasta vanustel lastel), ärrituvus, süstekoha reaktsioonid (punetus, naha kõvenemine, turse, valu ja valulikkus), unisus ja halb uni.
English: Additional studies in children looked at the effects of giving booster vaccinations, switching from Prevenar to Prevenar 13 and using Prevenar 13 alongside other vaccines routinely given to children.
Estonian: Täiendavates laste uuringutes vaadeldi revaktsineerimise mõju, vaktsiinilt Prevenar vaktsiinile Prevenar 13 üleminekut ja vaktsiini Prevenar 13 kasutamist koos laste muude korraliste vaktsiinidega.
English: In children below two years of age, the vaccine is given by injection into the thigh muscle.
Estonian: Alla 2-aastastele lastele manustatakse vaktsiini süstina reielihasesse.
English: A third study, which involved 900 adults aged 18 to 49, compared the immune response to Prevenar 13 with the response in adults aged 60 to 64.
Estonian: Kolmandas uuringus, milles osales 900 täiskasvanut vanuses 18-49 aastat, võrreldi nende ja 60-64-aastaste täiskasvanute immuunvastust vaktsiinile Prevenar 13.
English: The immune system will then be able to produce antibodies more quickly when it is exposed to the bacterium.
Estonian: Kui immuunsüsteem puutub bakteriga kokku hiljem uuesti, tekivad organismis antikehad kiiremini.
English: Prevenar 13 must not be used in people who are hypersensitive (allergic) to the active substances, to any of the other ingredients or to diphtheria toxoid (a weakened toxin from the bacterium that causes diphtheria).
Estonian: Vaktsiini Prevenar 13 ei tohi kasutada patsiendid, kes on vaktsiini toimeainete, selle mis tahes muu koostisaine või difteeriatoksoidi (difteeriat põhjustava bakteri nõrgestatud toksiin) suhtes ülitundlikud (allergilised).
English: The fourth study in adults over 65 years of age showed that Prevenar 13 reduced the incidence of pneumonia by almost half: 49 out of 42,240 (around 0.1%) subjects fell ill with pneumonia caused by
Estonian: Neljandas, üle 65-aastaste täiskasvanute uuringus tõendati, et Prevenar 13 vähendas kopsupõletiku esinemissagedust peaaegu poole võrra: vaktsiinirühmas haigestus 42 240 patsiendist bakteri S. pneumoniae põhjustatud kopsupõletikku 49 (ligikaudu 0,1%) patsienti võrreldes platseeborühmaga, kus 42 256 patsiendist haigestus 90 (ligikaudu 0,2%).
English: Adults aged 18 to 49 had an immune response with Prevenar 13 which was as good as the response in adults aged 60 to 64.
Estonian: 18-49aastaste täiskasvanute immuunvastus vaktsiinile Prevenar 13 oli sama hea kui 60-64-aastaste täiskasvanute oma.
English: • children aged between seven months and 11 months should first receive two doses with an interval of at least one month followed by a third dose in the second year;
Estonian: • 7-11-kuused lapsed peavad kõigepealt saama kaks annust vaheajaga vähemalt üks kuu.
English: Prevenar 13 contains small amounts of polysaccharides (a type of sugar) extracted from the ‘capsule' that surrounds the S. pneumoniae bacterium.
Estonian: Prevenar 13 sisaldab vähesel hulgal polüsahhariide (teatud suhkruliik), mis on eraldatud bakteri S. pneumoniae kestast.
English: What is the risk associated with Prevenar 13?
Estonian: Mis riskid vaktsiiniga Prevenar 13 kaasnevad?
English: All six of the additional polysaccharides in Prevenar 13 produced a response at least as good as the lowest response seen with Prevenar in the first main study.
Estonian: Vaktsiini Prevenar 13 kõik 6 täiendavat polüsahhariidi andsid vähemalt sama hea vastuse kui Prevenari mis tahes polüsahhariidi vähim vastus esimeses põhiuuringus.
English: What is Prevenar 13?
Estonian: Mis on Prevenar 13?
English: In adults aged 50 and older, in the first two main studies Prevenar 13 produced an immune response that was at least as good as the 23-valent polysaccharide vaccine for all 12 of the S. pneumoniae polysaccharides they share in common, and for several of these serotypes the immune response was better with Prevenar 13.
Estonian: Vähemalt 50-aastaste täiskasvanute kahes esimeses põhiuuringus tekitas Prevenar 13 vähemalt sama hea immuunvastuse kui 23-valentne polüsahhariidvaktsiin bakteri S. pneumoniae kõigi 12 ühise polüsahhariidi korral ja mitme serotüübi korral oli vaktsiini Prevenar 13 immuunvastus parem.
English: Adults and children aged two years and above should receive one single dose of Prevenar 13 into the shoulder muscle.
Estonian: Täiskasvanutele ja vähemalt 2-aastastele lastele tuleb anda Prevenar 13 üks üksikannus deltalihasesse (õlalihasesse).
English: For the full list of all side effects reported with Prevenar 13, see the package leaflet.
Estonian: Vaktsiini Prevenar 13 kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: In children aged between five and 17 years old, Prevenar 13 produced a response that was at least as good as Prevenar for all seven S. pneumoniae polysaccharides they share in common.
Estonian: 5-17-aastastel lastel andis Prevenar 13 vastuse, mis oli vähemalt sama hea kui bakteri S. pneumoniae Prevenaris sisalduva kõigi 7 ühise polüsahhariidi vastus.
English: Prevenar 13 is used to protect children aged between six weeks and 17 years against invasive disease, pneumonia (infection of the lungs) and acute otitis media (infection of the middle ear) caused by S. pneumoniae.
Estonian: Vaktsiini Prevenar 13 kasutatakse 6-nädalaste kuni 17-aastaste laste kaitsmiseks bakteri S. pneumoniae põhjustatud invasiivse haiguse, kopsupõletiku ja ägeda keskkõrvapõletiku eest.
English: In children under five years of age, Prevenar 13 produced a response that was at least as good as Prevenar for six of the seven S. pneumoniae polysaccharides they share in common in the first main study, and for five of the seven in the second.
Estonian: Alla 5-aastastel lastel tekitas Prevenar 13 esimeses põhiuuringus vähemalt sama hea vastuse kui Prevenar 6 polüsahhariidi korral 7st mõlemas vaktsiinis sisalduvast bakteri S. pneumoniae polüsahhariidist ja teises põhiuuringus 5 polüsahhariidi korral 7st.
English: The studies compared the immune response for Prevenar 13 with that for Prevenar against the seven polysaccharides that they share in common.
Estonian: Uuringutes võrreldi vaktsiinile Prevenar 13 tekkivat immuunvastust Prevenari immuunvastusega mõlema vaktsiini ühise 7 polüsahhariidi osas.
English: People who have a severe fever should not receive the vaccine until they have recovered, but they can still be given the vaccine if they have a mild infection such as a cold.
Estonian: Vaktsiini tohib kasutada kerge nakkuse, näiteks külmetuse korral.
English: All six of the additional polysaccharides in Prevenar 13 produced a response that was similar to the response seen with Prevenar against the seven polysaccharides.
Estonian: Vaktsiini Prevenar 13 kõigi 6 täiendava polüsahhariidi vastus sarnanes Prevenari vastusega 7 polüsahhariidile.
English: How has Prevenar 13 been studied?
Estonian: Kuidas vaktsiini Prevenar 13 uuriti?
English: What benefit has Prevenar 13 shown during the studies?
Estonian: Milles seisneb uuringute põhjal vaktsiini Prevenar 13 kasulikkus?
English: How is Prevenar 13 used?
Estonian: Kuidas vaktsiini Prevenar 13 kasutatakse?
English: What is Prevenar 13 used for?
Estonian: Milleks vaktsiini Prevenar 13 kasutatakse?
English: The immune response to the additional six polysaccharides in Prevenar 13 was compared with the lowest immune response to any of the polysaccharides in Prevenar.
Estonian: Vaktsiinis Prevenar 13 sisalduvale 6 muule polüsahhariidile tekkivat immuunvastust võrreldi Prevenari polüsahhariididele tekkivatest immuunvastustest vähimaga.
English: The vaccine can only be obtained with a prescription.
Estonian: Vaktsiini ei tohi kasutada kõrge palavikuga patsiendid enne paranemist.
English: The full EPAR for Docetaxel Mylan can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Docetaxel Mylani kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Docetaxel Mylan is given as a one-hour infusion every three weeks.
Estonian: Docetaxel Mylanit manustatakse üks tund kestva infusioonina iga kolme nädala tagant.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Docetaxel Mylan on 31 January 2012.
Estonian: Euroopa Komisjon andis Docetaxel Mylani müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 31. jaanuaril 2012.
English: • non-small-cell lung cancer.
Estonian: • mitteväikerakk-kopsuvähk.
English: It can also be used with other anticancer medicines (doxorubicin, cyclophosphamide, trastuzumab or capecitabine) in patients who have not yet received any treatment for their cancer or after other treatments have failed, depending on the type and stage of the breast cancer being treated;
Estonian: Ravimit tohib kasutada ka koos teiste vähiravimitega (doksorubitsiin, tsüklofosfamiid, trastusumaab või kapetsitabiin) patsientidel, kellel ei ole vähki veel ravitud, või pärast muude raviskeemide ebaõnnestumist, olenevalt ravitava rinnavähi vormist ja staadiumist;
English: Docetaxel Mylan is only used when the neutrophil count (the level of a type of white blood cell in the blood) is normal (at least 1,500 cells/mm3).
Estonian: Docetaxel Mylanit kasutatakse ainult sel juhul, kui neutrofiilide (valgeliblede liik) sisaldus veres on normaalne (vähemalt 1500 rakku/mm3).
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Docetaxel Mylan.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: It is available as a concentrate to make up into a solution for infusion (drip into a vein).
Estonian: Seda turustatakse kontsentraadina, millest valmistatakse infusioonilahus (veeni tilgutatav lahus).
English: The company provided data from the published literature on docetaxel.
Estonian: Ettevõte esitas dotsetakseeli kohta avaldatud kirjandusest pärinevad andmed.
English: • gastric adenocarcinoma (a type of stomach cancer) in patients who have not yet received any treatment for their cancer.
Estonian: • mao adenokartsinoom (maovähi vorm) patsientidel, kes ei ole veel vähiravi saanud.
English: For more information about treatment with Docetaxel Mylan, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Docetaxel Mylaniga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: The dose, duration of treatment and the medicines it is used with depend on the type of cancer being treated.
Estonian: Annus, ravi kestus ja ravimi kasutamine koos teiste ravimitega oleneb ravitavast vähivormist.